Novartis AG (NYSE:NVS) Shares Sold by BSW Wealth Partners

BSW Wealth Partners decreased its position in shares of Novartis AG (NYSE:NVS) by 7.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,169 shares of the company’s stock after selling 558 shares during the quarter. BSW Wealth Partners’ holdings in Novartis were worth $698,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Legacy Investment Solutions LLC acquired a new position in Novartis during the third quarter worth approximately $28,000. Union Bancaire Privee UBP SA acquired a new position in shares of Novartis in the 4th quarter valued at $27,000. Fortitude Family Office LLC boosted its stake in Novartis by 503.8% during the 3rd quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock worth $37,000 after purchasing an additional 267 shares during the period. Clean Yield Group purchased a new position in Novartis during the 3rd quarter worth $43,000. Finally, Brooklyn Investment Group acquired a new position in Novartis in the fourth quarter valued at $55,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. BMO Capital Markets raised their price target on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a report on Wednesday, October 30th. Erste Group Bank restated a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. Finally, HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Two investment analysts have rated the stock with a sell rating and six have issued a hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $123.38.

Novartis Trading Down 1.5 %

NYSE:NVS opened at $101.85 on Wednesday. The stock has a market capitalization of $208.19 billion, a price-to-earnings ratio of 11.83, a PEG ratio of 1.42 and a beta of 0.57. Novartis AG has a 1 year low of $92.35 and a 1 year high of $120.92. The stock has a fifty day moving average price of $100.10 and a two-hundred day moving average price of $108.64. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.90 and a current ratio of 1.11.

Novartis (NYSE:NVS) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The firm had revenue of $12.82 billion for the quarter, compared to the consensus estimate of $12.62 billion. During the same quarter in the previous year, the firm earned $1.74 earnings per share. As a group, sell-side analysts anticipate that Novartis AG will post 7.62 earnings per share for the current fiscal year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.